31.03.2016
Evonik Industries AG DE000EVNK013
DGAP-News: Evonik Industries AG: Evonik starts up plant producing methionine source for shrimps
DGAP-News: Evonik Industries AG / Key word(s): Product Launch
Evonik Industries AG: Evonik starts up plant producing methionine source for
shrimps
31.03.2016 / 09:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Evonik starts up plant producing methionine source for shrimps
- First plant for production of a methionine source for shrimps starts up
in Antwerp.
- New product from Evonik increases efficiency and sustainability of
crustacean aquaculture.
- Market launch of AQUAVI(R) Met-Met planned for mid-2016.
Essen. Evonik Industries has started up in Antwerp (Belgium) the world's
first production plant for a new methionine source specifically for shrimps
and other crustaceans. AQUAVI(R) Met-Met, the dipeptide of two
DL-methionine molecules, is expected to be launched on the market in
mid-2016 and will be used as an aquaculture feed additive.
Dr. Reiner Beste, Chairman of the Board of Management of Evonik Nutrition &
Care GmbH, says: "With AQUAVI(R) Met-Met we're extending our range of feed
amino acids for animal nutrition to include another specialty with high
value for our customers. This further strengthens our position as a market
and technology leader."
"In AQUAVI(R) Met-Met we're offering a cost-efficient and sustainable
solution also for shrimp and crustacean farming," says Dr. Emmanuel Auer,
Head of the Animal Nutrition Business Line at Evonik. "In view of the
growing global population and limited availability of resources, this
appears to us to be vitally important."
In 2015, no less than half of the fish, crustaceans, and shellfish consumed
globally originated from aquaculture. Fishmeal being part of the feed as a
protein source is a significant cost factor for farmers. Supplementation
with amino acids allows significant reduction of the proportion of fishmeal
in feeds, as Evonik has already demonstrated for fish farming. In addition,
Evonik contributes to improved sustainability and conservation of
biodiversity.
But shrimps and crustaceans have totally different feeding habits and
digestive systems than, for example, fish and AQUAVI(R) Met-Met has been
developed specially for them. It is significantly less water-soluble than
DL-methionine and not so easily leached out of the feed. In the digestive
tract of shrimps the dipeptide breaks down and methionine becomes available
for protein synthesis at exactly the right time. As feeding trials in many
countries have shown, just 0.56 kg of AQUAVI(R) Met-Met in 1,000 kg of
shrimp feed results in the same growth as 1 kg of DL-methionine. This
increases the efficiency and sustainability of shrimp farming.
AQUAVI(R) Met-Met has already been registered as a feed additive in many
countries, with more to follow. The new methionine source will initially be
available for shrimps and crustaceans but its efficiency is currently being
tested for other species.
Evonik translates over 60 years of experience in manufacturing essential
amino acids for animal nutrition into solutions that meet the evolving
needs of its customers in over one hundred countries. As Evonik now expands
its scope to innovative nutritional feed additive solutions beyond amino
acids, customers can count on Evonik to take nutrient effectiveness ever
further and keep delivering value along with consistent quality. Around the
planet, Evonik products and services are and will continue to be key to
producing healthy, affordable food with fewer natural resources and a
smaller environmental footprint.
Company information
Evonik, the creative industrial group from Germany, is one of the world
leaders
in specialty chemicals. Profitable growth and a sustained increase in the
value of the company form the heart of Evonik's corporate strategy. Its
activities focus on the key megatrends health, nutrition, resource
efficiency and globalization. Evonik benefits specifically from its
innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2015
more than 33,500 employees generated sales of around EUR13.5 billion and an
operating profit (adjusted EBITDA) of about EUR2.47 billion.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and
contributes to fulfilling basic human needs. That includes applications for
everyday consumer goods as well as animal nutrition and health care. This
segment employed about 7,000 employees, and generated sales of around
EUR4.9 billion in 2015.
Disclaimer
In so far as forecasts or expectations are expressed in this Investor
Relations News or where our statements concern the future, these forecasts,
expectations or statements may involve known or unknown risks and
uncertainties. Actual results or developments may vary, depending on
changes in the operating environment. Neither Evonik Industries AG nor its
group companies assume an obligation to update the forecasts, expectations
or statements contained in this release.
Contact:
Tim Lange
Head of Investor Relations
+49 201 177-3150
[email protected]
Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Telefax +49 201 177-3475
www.evonik.com
Supervisory Board
Dr. Werner Müller, Chairman
Executive Board
Dr. Klaus Engel, Chairman
Dr. Ralph Sven Kaufmann
Christian Kullmann
Thomas Wessel
Ute Wolf
Registered office Essen
Registered court
Essen local court
Commercial registry B 19474
VAT ID no. DE 811160003
---------------------------------------------------------------------------
31.03.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone: +49 (0) 201 177-01
Fax: +49 (0) 201 177-3475
E-mail: [email protected]
Internet: www.evonik.com
ISIN: DE000EVNK013, XS0911405784
WKN: EVNK01, A1TM7T
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Hamburg, Hanover, Munich,
Stuttgart; Terminbörse EUREX; Luxemburg
End of News DGAP News Service
---------------------------------------------------------------------------
449611 31.03.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evonik Industries AG ISIN: DE000EVNK013 können Sie bei EQS abrufen
Chemie , EVNK01 , EVK , XETR:EVK